Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 244

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 244
---
 to the unaudited pro forma combined financial information.

104 Notes to Unaudited Pro Forma Combined Financial Information Description of Business Combination On March 25, 2024, APx, OmnigenicsAI and Merger Sub entered into the Business Combination Agreement. Subject to the terms and conditions of the Business Combination Agreement, at the Merger Effective Time: •each SPAC Unit issued and outstanding immediately prior to the Merger Effective Time shall be automatically separated and the holder thereof shall be deemed to hold one SPAC Class A Ordinary Share and one -halfof a SPAC Warrant; provided that no fractional SPAC Warrants shall be issued in connection with such separation such that if a holder of such SPAC Units would be entitled to receive a fractional SPAC Warrant upon such separation, the number of SPAC Warrants to be issued to such holder upon such separation will be rounded down to the nearest whole number of SPAC Warrants; •immediately following the separation of each SPAC Unit, each SPAC Class A Ordinary Share, issued and outstanding immediately prior to the Merger Effective Time shall be automatically surrendered, cancelled and cease to exist in exchange for the right to receive, upon delivery of the applicable Letter of Transmittal, one newly issued Company Share. Each SPAC Shareholder shall cease to have any other rights in and to such SPAC Ordinary Shares, except as expressly provided in the Business Combination Agreement; and •immediately following the separation of each SPAC Unit, each SPAC Warrant issued and outstanding immediately prior to the Merger Effective Time shall cease to be a warrant with respect to SPAC Ordinary Shares and be assumed by the Company and converted into a validly issued and fully paid warrant to purchase Company Shares. Each Company Warrant shall continue to have and be subject to substantially the same terms and conditions as were applicable to such SPAC Warrant immediately prior to the Merger Effective Time (including any repurchase rights and cashless exercise provisions) in accordance with the provisions of the SPAC Warrant Agreement and the Assignment, Assumption and Amendment Agreement. For more information on the Business Combination, see “ The Business Combination Agreement.” Basis of Presentation The adjustments presented on the pro forma combined financial statements have been identified and presented to provide an understanding of the Combined Company upon consummation of the Business Combination for illustrative purposes. The following unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S -Xto depict the accounting for the transaction (the “Transaction